OGDEN, Utah--(BUSINESS WIRE)--Setpoint Systems (http://www.setpointusa.com), a leader in design and manufacture of custom lean automation solutions and manufacturing ...

The U.S. Food and Drug Administration has approved the SetPoint System, a neuroimmune modulation device for the treatment of adults living with moderate-to-severe rheumatoid arthritis (RA). The ...

SetPoint Medical today announced the first patients in Chicago have been treated with the SetPoint System, an FDA-approved neuroimmune modulation therapy for adults living with moderately-to-severely ...

Credit: SetPoint Medical. The SetPoint System is a rechargeable neurostimulation device that is implanted on the vagus nerve. Treatment with the SetPoint System, a neuroimmune modulation device, was ...

SetPoint Medical has secured $140m through private financing, earmarked for the commercial rollout of the SetPoint System, a neuroimmune modulation therapy designed for patients with ...

SetPoint Medical has been given an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) greenlighting it to begin a clinical trial to test its modulation platform in ...

An innovative new device calms inflammation by delivering a low-voltage jolt of electricity to the vagus nerve. The FDA has approved the SetPoint System, a device implanted in the neck for relieving ...

SetPoint Medical has raised $140 million. This includes $25 million in the second tranche of its Series C financing, as well as $115 million in its Series D financing, co-led by Elevage Medical ...

Procedures performed by Dr. Webster Crowley mark a milestone for neuroimmune modulation therapy in the Midwest SetPoint Medical today announced the first patients in Chicago have been treated with the ...